Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Enhanced detection of dermal-binding autoantibodies in pemphigoid diseases with a modified indirect immunofluorescence cell-based mosaic assay using IgG4 and optimized testing conditions: a single-centre retrospective study
Agrawal, Shruti , Camilleri, M. J., Comfere, Nneka I. , Johnson, Emma F. , Kalaaji, Amer N., Wieland, Carilyn N. , Lange, Colleen R., Miller, C., Shore, Carly J, Guerrico, Anatilde M Gonzalez, Lange, Colleen, Miller, Cameron, Gonzalez Guerrico, Anatilde M, Lehman, Julia S. , Guerrico, Anatilde M. Gonzalez

Mayo Clinic

British Journal of Dermatology | January 9, 2026 | Volume: 195 | Issue: 1 | Pages: 187-188

10.1093/bjd/ljag007 | PMID 41517990 Get It

Patzelt et al. previously characterized dermal-binding autoantibodies using an indirect immunofluorescence (IIF) mosaic assay with cells transfected with p200-laminin β4, laminin-332 or collagen VII subunits among specimens showing a dermal pattern on IIF using salt-split skin (IIF-SSS) and IgG. This study expanded testing to include specimens with either a dermal or mixed pattern on IIF-SSS and demonstrated improved test sensitivity with modified testing methods.
Oral rehydration solution for the management of fluid and electrolyte disturbances in patients with an ileostomy: A scoping review
Hoeg, Austin , Jaques, Jessica, Johnson, Remy, Kocher, Megan , Vaughn, Byron P. , Khoruts, Alexander , Jahansouz, Cyrus , Rd, Hurt, Teigen, Levi , Hoeg, Austin J , Hurt, Ryan T. , Teigen, Levi M , Weingarden, Alexa R.

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | January 9, 2026 | Volume: 50 | Issue: 3 | Pages: 339-351

10.1002/jpen.70050 | PMID 41508901 Get It

Abstract Ileostomy creation is common among patients with colorectal cancer, diverticulitis, and inflammatory bowel disease. Surgical removal or diversion of the colon can result in nutrition complications, most notably dehydration—a leading cause of hospital readmission—and increased risk of kidney injury. Existing studies on fluid and electrolyte management after ileostomy largely focus on short bowel syndrome or high‐output stomas, overlooking the physiological implications of ileostomy creation, even in patients with normal output. Given the absence of standardized oral rehydration protocols and limited interventional data, a scoping review was conducted to map the current evidence on oral rehydration solutions for postoperative fluid and electrolyte management in adults without short bowel syndrome or high‐output stoma. Comprehensive searches across five databases identified 5738 articles, of which 6 met inclusion criteria. Eligible studies examined adults with ileostomy for any standard indication in which oral rehydration solution use was a study objective. The included studies were methodologically heterogeneous, encompassing randomized controlled, crossover, double‐blinded comparator, retrospective cohort, and qualitative designs. Collectively, available evidence supports a pivotal role for oral rehydration solutions in both short‐term and long‐term management after ileostomy, improving hydration and reducing complications. This review highlights the need for standardized, evidence‐based oral rehydration regimens and underscores opportunities to reduce postoperative morbidity, kidney injury, and hospital readmissions while optimizing long‐term outcomes in this growing patient population.
Sex, education and race/ethnicity have distinct effects on amyloid and tau‐PET status
Groot, Colin , Rowe, Christopher C., Giessen, Elsmarieke van de, Flier, Wiesje M. van der, Pijnenburg, Yolande A.L., Visser, Pieter Jelle, Braber, Anouk den, Pontecorvo, Michael J. , Burnham, Samantha C., Lu, Ming , Jagust, William J., Baker, Suzanne L. , Harrison, Theresa, Gispert, Juan Domingo, Shekari, Mahnaz , Minguillón, Carolina, Smith, Ruben, Mattsson‐Carlgren, Niklas, Palmqvist, Sebastian, Strandberg, Olof, Stomrud, Erik, Brickman, Adam, Manly, Jennifer J., Lao, Patrick J., Kreisl, William Charles, Malpetti, Maura, O'Brien, John T, Jäger, Elena, Bischof, Gérard, Drzezga, Alexander, Xie, Fang, Mao, Xiaoxie, Guan, Yihui, Frisoni, Giovanni B, Peretti, Débora Elisa , Skoog, I., Kern, Silke, Sperling, Reisa A., Johnson, Keith A., Risacher, Shannon, Saykin, Andrew J., Carrillo, Maria C., Dickerson, Brad C., Apostolova, Liana G., Rabinovici, Gil D., Barthel, H, Messerschmidt, Konstantin, Vandenberghe, Rik, Laere, Koen J. Van, Spruyt, Laure , Petersen, Ronald, Jack, Clifford R., Franzmeier, Nicolai, Brendel, Matthias, Gnörich, Johannes, Benzinger, Tammie L.S., Lagarde, Julien, Sarazin, Marie , Villeneuve, Sylvia , Poirier, Judes, Seo, Sang Won, Gu, Yuna , Kim, Jun Pyo, Mormino, Beth C., Vossler, Hillary , Rosa‐Neto, Pedro, Therriault, Joseph, Rahmouni, Nesrine, Cash, David M, Schott, Jonathan M, Hanseeuw, Bernard J, Jansen, Willemijn J. , Joie, Renaud La, Rosen, Howard J., Johnson, Sterling C., Christian, Bradley T, Betthauser, Tobey J., Landau, Susan M., O'Bryant, Sid E., Hansson, Oskar H., Ossenkoppele, Rik, Prevent‐AD, ADNI, ADNI‐DOD, A‐Study, MCSA,, O’Brien, John T. , O'Brien, John Tiernan , Groot, Colin , Coomans, Emma M. , Rowe, Christopher C., Doré, Vincent , Feizpour, Azadeh , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Pijnenburg, Yolande A.L. , Visser, Pieter Jelle , Braber, Anouk den , Burnham, Samantha C. , Kennedy, Ian Andrew , Jagust, William J. , Harrison, Theresa M. , Gispert, Juan Domingo , Shekari, Mahnaz , Minguillón, Carolina , Smith, Ruben, Mattsson, Niklas , Palmqvist, Sebastian , Strandberg, Olof, Stomrud, Erik , Brickman, Adam M. , Luchsinger, Jose Alejandro , Manly, Jennifer J. , Lao, Patrick , Malpetti, Maura , Rowe, James B. , Bischof, Gérard N. , Drzezga, Alexander E. , Xie, Fang , Guan, Yihui , Garibotto, Valentina , Frisoni, Giovanni B. , Schöll, Michael , Kern, Silke , Sperling, Reisa Anne , Johnson, Keith A. , Risacher, Shannon L. , Saykin, Andrew J. , Carrillo, María C. , Dickerson, Bradford Clark , Apostolova, Liana G. , Rabinovici, Gil D. , Rullmann, Michael , Messerschmidt, Konstantin, Vandenberghe, Rik , Petersen, Ronald, Jack, Clifford R. , Franzmeier, Nicolai , Brendel, Matthias , Gnörich, Johannes , Benzinger, Tammie L.S. , Lagarde, Julien , Bottlaender, Michel , Poirier, Judes , Seo, Sang Won , Kim, Jun Pyo, Young, Christina B. , Rosa-Neto, Pedro , Therriault, Joseph , Rahmouni, Nesrine , Coath, William , Cash, David M. , Schott, Jonathan M. , Hanseeuw, Bernard , Salman, Yasmine , Malotaux, Vincent , Joie, Renaud La , Rosen, Howard J. , Johnson, Sterling C. , Christian, Bradley T. , Betthauser, Tobey J. , Landau, Susan , O’Bryant, Sid E. , Hansson, Oskar , Ossenkoppele, Rik

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_105387 Get It

Abstract Background Sex, education and race/ethnicity are all associated with risk of Alzheimer's disease dementia. Here, we assess the effects of self‐reported sex, educational attainment and race/ethnicity on amyloid‐positivity, and tau‐PET‐positivity in 12,048 (7,394 cognitively unimpaired [CU], 2,177 MCI, and 2,477 dementia) individuals from 42 cohorts worldwide. Method Logistic generalized estimating equations were used to estimate frequency of amyloid‐positivity (using cohort‐specific thresholds for amyloid‐PET [84%] or CSF) and tau‐PET‐positivity (cohort‐specific thresholds of 2SD above mean temporal uptake in amyloid‐negative controls). We assessed: i) sex and APOEε4 ( N = 10,098) associations, to complement earlier findings of a higher frequency of tau‐positivity in females, ii) effects of lower/higher education ( N = 10,970; cohort‐specific median‐split), and iii) effects of race/ethnicity (non‐Hispanic White [hereafter: White], N = 4880; Asian, N = 116; Black or African‐American [hereafter: Black], N = 353; Hispanic, N = 356, only from Northern‐American cohorts). Outcomes were frequency of amyloid‐positivity in CU individuals only, and tau‐PET‐positivity in both amyloid‐positive (AB+) CU and cognitively impaired (CI, i.e. MCI and dementia) individuals. Interaction effects on the relationship between age and amyloid/tau‐positivity were assessed and only retained in the models when significant. Result Female sex was associated with an APOEε4 ‐independent increased frequency of amyloid‐positivity (β=0.51[0.22], p = 0.02) in CU and increase of tau‐positivity in both AB+CU (β=0.27[0.08]) and AB+CI (β=0.37[0.08], both p <0.01). Remarkably, tau‐positivity frequencies of female APOEε4 non‐carriers were equivalent to male APOEε4 carriers in AB+CI (Figure 1). No significant sex* APOE interactions were observed. In CU, higher education was associated with lower amyloid‐positivity frequency (β=‐0.12[0.05], p = 0.02). In contrast, among AB+CU, there was an age*education interaction effect that indicated more pronounced age effects on tau‐positivity in individuals with higher education (age*education:β interaction =0.03[0.01], p <0.01). There were no education effects in AB+CI (Figure 2). In CU, an age*race/ethnicity interaction effect was observed across all non‐White groups compared to White (Hispanic:β interaction =‐0.05[0.01], p <0.01; Black:‐0.04[0.01], p <0.01; Asian:‐0.02[0.01], p = 0.04). This suggests that the impact of age on amyloid‐positivity was less pronounced in non‐White groups. Furthermore, in AB+CI, Hispanic ethnicity was related to higher tau‐positivity frequency than White (β=0.51[0.22], p = 0.02; Figure 3). Conclusion In this multi‐center initiative comprised of clinical and community‐based cohorts, we observed that self‐reported sex, educational attainment and race/ethnicity were related to positivity‐frequencies of Alzheimer's disease pathology.
Characterizing amyloid and tau positron emission tomography‐based stages across the clinical continuum
Cody, Karly Alex , Sokołowski, Andrzej , Johns, Emily , Guerra, Lucah Medina, Dumitrescu, Logan, Durant, Alaina, Sathe, Aditi, Koran, Mary Ellen I. , Mez, Jesse, Saykin, Andrew J., Toga, Arthur W., Cuccaro, M. L., Tosun, Duygu, Insel, Philip S., Johnson, Sterling C., Harrison, Theresa, Hohman, Timothy J., Mormino, Elizabeth C., Cody, Karly A , Sokołowski, Andrzej, Winer, Joseph R. , Young, Christina B. , Younes, Kyan , Dumitrescu, Logan , Archer, Derek B. , Durant, Alaina, Mez, Jesse , Saykin, Andrew J. , Toga, Arthur W. , Cuccaro, Michael L. , Insel, Philip S. , Johnson, Sterling C. , Harrison, Theresa M. , Hohman, Timothy J. , Mormino, Elizabeth C.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71017 | PMID 41505234 Get It

Abstract INTRODUCTION We standardized positron emission tomography (PET) data across multiple cohorts and tracers to characterize the frequency of amyloid and tau PET severity along the clinical continuum. METHODS Clinical stage was defined using cohort‐specific criteria and included cognitively unimpaired (CU), mild cognitive impairment (MCI), and dementia. Amyloid severity was staged using Centiloids (CL). Tau severity was staged using a hierarchical Braak‐based schema. The cumulative probabilities of PET‐based stages were estimated using ordinal logistic regressions. RESULTS Among 10,396 individuals (mean [standard deviation] age: 71.9 [7.1] years), amyloid levels ≥ 25 CL increased with age among CU and MCI, while amyloid levels ≥ 100 CL were most common in dementia. In 3295 with tau PET, tau severity increased with amyloid and clinical stage and showed complex associations with age. Within each clinical stage, the full spectrum of amyloid and tau PET severity was observed. DISCUSSION PET‐based staging revealed heterogeneous amyloid and tau burden along the clinical continuum. Highlights PET‐based staging is feasible across multiple cohorts and PET tracers. There is heterogeneity in amyloid and tau severity across the clinical spectrum. The frequency of amyloid and tau PET severity increased with clinical severity. The likelihood of tau PET severity differed by age, amyloid, and clinical severity.
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Leuzy, Antoine , Raket, Lars Lau, Villemagne, Victor L., Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Sanabria, Sandra , Boada, Mercè, Charil, A., Collins, Emily C., Collins, Jessica, Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Insel, Philip S., Irizarry, Michael C., Jack, Clifford R., Jagust, William J., Johnson, Keith A., Johnson, Sterling C., Karten, Yashmin, Marquié, Marta, Mathotaarachchi, Sulantha , Mintun, Mark A., Huang, Qi, Mao, Xiaxie, Gnörich, Johannes , Pappas, Ioannis, Petersen, Ronald, Chiotis, Konstantinos, Rabinovici, Gil D., Rosa‐Neto, Pedro, Schwarz, Christopher G, Smith, Ruben, Stephens, Andrew W., Whittington, Alex , Carrillo, M., Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Stephenson, Diane , Tatton, Nadine , Brendel, Matthias, Xie, Fang, Hansson, Oskar H., Rial, Alexis Moscoso , Rakêt, Lars Lau , Villemagne, Victor L. , Tonietto, Mattéo , Olafson, Emily, Lutz, Olivia , Boada, Merce , Betthauser, Tobey J. , Collins, Emily C. , Collins, Jessica, Gunn, Roger N. , Higuchi, Makoto, Hutchison, R. Matthew , Iaccarino, Leonardo , Insel, Philip S. , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Johnson, Keith A. , Johnson, Sterling C. , Marquié, Marta , Ossenkoppele, Rik , Pappas, Ioannis , Petersen, Ronald C. , Chiotis, Konstantinos , Rabinovici, Gil D. , Rosa-Neto, Pedro , Schwarz, Christopher G. , Smith, Ruben, Stephens, Andrew W., Carrillo, María C. , Kolb, Hartmuth C. , Brendel, Matthias , Xie, Fang , Rowe, Christopher Cleon , Hansson, Oskar , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_106362 Get It

Abstract Background The Joint Propagation Model (JPM)‐based CenTauR scale was recently introduced to harmonize tau‐PET quantification across different radiotracers. This study examined how CenTauR harmonization enhances the comparability of tau‐PET quantification across matched cohorts using different tracers. The evaluation focused on three key aspects: (1) comparing tau‐PET positivity rates as defined by CenTauR, (2) evaluating its diagnostic accuracy for symptomatic AD, and (3) analyzing longitudinal changes in tau‐PET rates over time. Method The JPM, developed by the CPAD‐led Tau PET Harmonization Working Group (Leuzy et al., Alzheimers Dement. 2024; Figure 1A), models relationships between anchor point subjects and head‐to‐head tau‐PET SUVR data onto the CenTauR scale, providing conversion equations for multiple tracers. JPM equations were applied to [ 18 F]flortaucipir SUVR (Meta‐temporal ROI) data from 561 cognitively impaired participants in the ADNI and OASIS‐3 studies. Using ROC analysis, we determined the CenTauR cut‐off for positivity (T+) that maximized the Youden index for discriminating between FDA‐approved positive/negative visual reads. Three separate cohorts, scanned using [ 18 F]flortaucipir (ADNI), [ 18 F]MK‐6240 (CPAS), and [ 18 F]RO‐948 (BioFINDER‐2), were matched 1:1 by age, MMSE, amyloid‐β, and clinical diagnosis. CenTauR‐based metrics were compared across these cohorts. Result A cut‐off of 18 CenTauRs was found to optimally classify [ 18 F]flortaucipir PET visual reads (Figure 1B). The matching procedure identified 1089 participants (363 per cohort). The frequency of T+ using the 18 CenTauRs cut‐off for the Meta‐Temporal ROI was highly comparable across tracers across groups, except for the Aβ‐positive cognitively unimpaired group, where variability was more pronounced due to a smaller sample size (Figure 2A). Similarly, tau‐PET discriminative accuracy for symptomatic AD vs controls remained similar across [ 18 F]flortaucipir and [ 18 F]MK‐6240 (Figure 2B). In a separate sample of 212 matched participants from ADNI ([ 18 F]flortaucipir) and AIBL ([ 18 F]MK‐6240) with baseline and 1‐year follow‐up tau‐PET scans, 1‐year change in CenTauRs was comparable (Figure 2C). An exploratory voxelwise transformation, utilizing the Meta‐Temporal conversion equation in a representative case scanned with both [ 18 F]flortaucipir and [ 18 F]MK‐6240, demonstrates the potential for voxelwise CenTauR harmonization (Figure 3). Conclusion These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. Additional validation analyses with larger cohorts including other radiotracers ([ 18 F]PI‐2620) are underway.
Multiomics alterations associated with tolerance and response to simulated progressive hemorrhage in healthy adult humans
Misganaw, Burook , Muhie, Seid , Gautam, Aarti , Miller, Stacy-Ann, Rosales, I. C. Bonilla, Dimitrov, George I., Sowe, Bintu, Johnson, Christopher P., Roberts, Shelly K., Regimbal, Riley J. , Wiggins, Chad C. , CONVERTINO, V, Joyner, Michael J , Curry, Timothy B. , Hammamieh, Rasha , Wiggins, Chad C , Gautam, Aarti, Miller, Stacy‐Ann , Dimitrov, George I., Johnson, Christopher P., Joyner, Michael J. , Convertino, Víctor A.

Mayo Clinic

Physiological Genomics | January 7, 2026 | Volume: 58 | Issue: 2 | Pages: 102-114

10.1152/physiolgenomics.00253.2025 | PMID 41494644 Get It

This study investigated the first multiomics data for association with tolerance to central hypovolemia in humans. Analyzing gene expression, proteins, and genetic variants in individuals with high and low tolerance to simulated hemorrhage, the findings show that severe blood loss causes widespread transcriptional changes, including the activation of innate immune system pathways and inhibition of gas transport processes. This research can help identify molecular factors that influence individuals’ tolerance levels for progressive blood loss.
C 11 Choline-PET/CT as a Localization Standard for Reoperative Primary Hyperparathyroidism
Hopmann, Peter , Foster, Trenton R. , Dy, Benzon M. , McKenzie, Travis, Wermers, Robert A. , Lyden, Melanie L. , Lund, Sarah , Foster, Trenton R , Lyden, Melanie, McKenzie, Travis J. , Johnson, Geoffrey B.

Mayo Clinic

The American Surgeon™ | January 6, 2026 | Volume: 92 | Issue: 6 | Pages: 1806-1812

10.1177/00031348251413528 | PMID 41490739 Get It

Introduction Previous studies have demonstrated that C 11 choline positron emission tomography/computed tomography (Choline-PET/CT) can localize abnormal parathyroid glands in the reoperative setting. This study assesses a large volume of patients with primary hyperparathyroidism (1HPT) who underwent Choline-PET/CT to confirm its utility in the setting of negative or equivocal conventional imaging. Methods All patients who underwent Choline-PET/CT for evaluation of 1HPT from July 2017 to July 2024 at a single institution were reviewed. Inclusion criteria were patients who underwent parathyroidectomy and had lab testing to assess for cure (defined as >50% drop from baseline PTH and into normal range, or resolution of hypercalcemia at follow-up). Sensitivity, positive predictive value (PPV), false negative rate (FNR), and accuracy were compared to conventional imaging (neck ultrasound, parathyroid scan, and parathyroid four-dimensional CT (4D-CT)). Subgroup analysis was conducted comparing sensitivity of modalities among index operations and separately in reoperations. Results 84 patients were included for analysis. 61 failed to localize on at least one conventional modality, and 15 failed to localize on all conventional studies. 67 patients (80%) achieved cure, of which 53 were reoperations. Choline-PET/CT outperformed conventional modalities across sensitivity, PPV, FNR, and accuracy. Choline-PET/CT also outperformed conventional modalities when comparing sensitivity in both subgroups. Conclusion C 11 choline-PET/CT is a valuable imaging modality in the reoperative setting and demonstrates utility for index operations. It provides localization when other modalities fail and allows for a high surgical cure rate. Further investigation into its utility as a primary imaging modality is warranted.
Senolytic‐Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers
Tripathi, Utkarsh , Suda, Masayoshi , Kulshreshtha, Vagisha , Piatkowski, Bryan T, Giorgadze, Nino, Inman, Christina L., Gasek, Nathan , Xu, Ming, Johnson, Kurt O. , Pirtskhalava, Tamar , Chaib, Selim , Prata, Larissa P. G. Langhi, Zhu, Yi , Kandhaya‐Pillai, Renuka , Tullius, S., Wyles, Saranya P. , Majji, Rambabu, Tchkonia, Tamar, Kirkland, James L., Inman, Christina, Chaib, Selim , Yalamanchili, Hari Krishna , Zhu, Yi , Suda, Masayoshi , Tripathi, Utkarsh , Piatkowski, Bryan , Palmer, Allyson K. , Prata, Larissa , Rambabu, Majji , Allison, David B. , Tchkonia, Tamar , Kirkland, James L.

Mayo Clinic

Aging Cell | December 30, 2025 | Volume: 25 | Issue: 1 | Pages: No page available

10.1111/acel.70358 | PMID 41462575 Get It

ABSTRACT The senescent cell (SC) fate is linked to aging, multiple disorders and diseases, and physical dysfunction. Senolytics, agents that selectively eliminate 30%–70% of SCs, act by transiently disabling the senescent cell antiapoptotic pathways (SCAPs), which defend those SCs that are proapoptotic and pro‐inflammatory from their own senescence‐associated secretory phenotype (SASP). Consistent with this, a JAK/STAT inhibitor, Ruxolitinib, which attenuates the pro‐inflammatory SASP of senescent human preadipocytes, caused them to become “senolytic‐resistant”. Administering senolytics to obese mice selectively decreased the abundance of the subset of SCs that is pro‐inflammatory. In cell cultures, the 30%–70% of human senescent preadipocytes or human umbilical vein endothelial cells (HUVECs) that are senolytic‐resistant (to Dasatinib or Quercetin, respectively) had increased p16 INK4a , p21 CIP1 , senescence‐associated β‐galactosidase (SAβgal), γH2AX, and proliferative arrest similarly to the total SC population (comprising senolytic‐sensitive plus‐resistant SCs). However, the SASP of senolytic‐resistant SCs entailed less pro‐inflammatory/apoptotic factor production, induced less inflammation in non‐senescent cells, and was equivalent or richer in growth/fibrotic factors. Senolytic‐resistant SCs released less mitochondrial DNA (mtDNA) and more highly expressed the anti‐inflammatory immune evasion signal, glycoprotein non‐melanoma‐B (GPNMB). Transplanting senolytic‐resistant SCs intraperitoneally into younger mice caused less physical dysfunction than transplanting the total SC population. Because Ruxolitinib attenuates SC release of proapoptotic SASP factors, while pathogen‐associated molecular pattern factors (PAMPs) can amplify the release of these factors rapidly (acting as “senosensitizers”), senolytic‐resistant and senolytic‐sensitive SCs appear to be interconvertible.
Antigen-specific CD8 T cells are generated and reactivated in the bone marrow following viral brain infections and impact the bone marrow niche
Anani‐Wolf, Delaney, Hotchkiss, Kelly , Reesman, Rachael , Moelker, Eliese , Hoyt-Miggelbrink, Alexandra M., Fain, Cori E. , Norberg, Pamela K., Wallace, Shannon E, Jain, Vatsal, Chandramohan, V., Johnson, Aaron J., Anani-Wolf, Delaney M, Reesman, Rachael A, Wolf, Delaney M. , Pfaller, Christian K. , Hoyt-Miggelbrink, Alexandra M. , Blethen, Kathryn E. , Wallace, Shannon , Grant, Gerald A. , Khasraw, Mustafa , Chandramohan, Vidyalakshmi , Johnson, Aaron J. , Ayasoufi, Katayoun

Mayo Clinic

No container title available | December 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.25.696510 | PMID 41509281 Get It

Abstract Bone marrow is the primary immune organ responsible for stem cell maintenance and hematopoiesis. However, the contribution of the bone marrow niche for the generation of adaptive immune responses is less well-understood. We therefore assessed the capacity of virus antigen-specific CD8 T cells to be generated and expanded in bone marrow following acute neurotropic virus infection. Intracranial infection with the neurotropic Theiler’s Murine Encephalomyelitis Virus (TMEV) results in an acute infection in the C57BL/6 mouse which is cleared within 4 weeks post infection due to the generation of an antigen-specific CD8 T cell response against the immunodominant epitope VP2 121-130 . We determined that 1-10% of CD8 T cells present in the femoral, and sternal bone marrow were virus antigen-specific 5-7 days after intracranial TMEV infection. We determined that antigen-specific CD8 T cells were generated in the bone marrow with similar kinetics to that of conventional responses in the secondary lymphoid organs. Importantly, continuous treatment with FTY720, which sequesters T cells outside of the blood, did not eliminate antigen-specific CD8 T cells in the bone marrow compartment indicating generation within the bone marrow niche. Similarly, injection of Poly I:C admixed with fluorescently labeled ovalbumin into the brain generated a similar antigen-specific CD8 T cell response in the bone marrow indicating these responses occur following various brain insults. This model also identified the likely antigen presenting cell (APC) responsible for scavenging antigens from the brain and trafficking into the bone marrow as a migratory myeloid-derived APC. Moreover, following clearance of TMEV infection, CD8 T cells in the bone marrow established durable memory. Antigen-specific memory CD8 T cells in the bone marrow reactivated and expanded upon cognate antigen reencounter. Antigen-specific reactivation of memory CD8 T cells within the bone marrow caused a concurrent increase in Lineage-, Sca-1+, c-Kit+ (LSK) and CD11b+ MHCII+ myeloid cells. This increase in the LSKs and myeloid cells in the bone marrow niche was abrogated with CD8 T cell depletion. We conclude that brain viral infections induce in situ effector and memory T cell responses within the bone marrow compartment. Memory recall CD8 T cell responses induce niche dysregulation by expanding LSK cells and lead to an influx of MHCII+ myeloid cells. Our data pave the way for crucial studies of bone marrow resident antigen-specific CD8 T cells in health and diseases.
Dietary Nitrate Intake and 16S rRNA ‐Inferred Nitrite‐Generating Capacity of the Subgingival Microbiome May Influence Glucose Metabolism: Results From the Oral Infections Glucose Intolerance and Insulin Re
Goh, Charlene En Hui, Molinsky, Rebecca , Roy, Sumith , Paster, B. J., Chen, Ching‐Yuan, Johnson, Stephen , Yuzefpolskaya, Melana, Colombo, P.C. , Rosenbaum, Michael, Knight, Rob , Desvarieux, Moïse, Jacobs, David R., Jacobs, David R. , Goh, Charlene Enhui , Goh, Charlene E , Paster, Bruce J , Jacobs, David R , Demmer, Ryan T , Molinsky, Rebecca L , Bohn, Bruno , Genkinger, Jeanine M. , Paster, Bruce J. , Rosenbaum, Michael , Desvarieux, Moı̈se, Papapanou, Panos N , Demmer, Ryan T.

Mayo Clinic

Journal of Clinical Periodontology | December 26, 2025 | Volume: 53 | Issue: 4 | Pages: 508-519

10.1111/jcpe.70084 | PMID 41448605 Get It

ABSTRACT Aims To investigate whether the association between the nitrite‐generating capacity of the subgingival microbiome and early cardiometabolic risk biomarkers varies by dietary nitrate intake. Materials and Methods Cross‐sectional data from 668 participants (mean age 31 ± 9 years, 73% women) were analysed. Dietary nitrate intake was calculated from food frequency questionnaires. Subgingival 16S rRNA sequencing (Illumina, MiSeq) and PICRUSt2 estimated microbial genes. The Microbiome‐Induced Nitric Oxide Enrichment Score (MINES) was calculated as a ratio of microbial gene abundances representing enhanced net capacity for NO generation. Adjusted multivariable linear models regressed cardiometabolic risk biomarkers (HbA1c, glucose, insulin, insulin resistance (HOMA‐IR), blood pressure) on nitrate intake and MINES together with a MINES × nitrate intake interaction term. Results Mean nitrate intake was 190 ± 171 mg/day. Significant interactions of MINES and nitrate intake were observed for insulin and HOMA‐IR ( p < 0.05). Among participants with a low MINES, higher nitrate intake was associated with lower HOMA‐IR (1.2 [1.1–1.4] vs. 1.5 [1.3–1.6]; p = 0.002), but levels were similar in those with high MINES ( p = 0.84). Conclusions A biomarker of higher microbial NO‐generating capacity in subgingival plaque is associated with lower insulin and insulin resistance among individuals with lower dietary nitrate intake. Future trials evaluating the cardiometabolic benefits of nitrate‐rich diets should incorporate measures of the entire oral microbiome.